To Get Full Access :

Alyftrek

Alyftrek is a daily oral treatment for cystic fibrosis in patients aged 6 and older with the F508del mutation or other responsive CFTR variants. It helps restore CFTR protein function to improve lung performance and reduce disease flare-ups.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Vanzacaftor, Tezacaftor, And DeutIVacaftor
  • Innovator :

    VERTEX PHARMACEUTICALS INC
  • Approval Date :

    20-Dec-24
  • NCE-1 Date :

    20-Dec-28
  • NCE Date :

    20-Dec-29
  • Dosage Form :

    Oral Tablet
  • Strength :

    50MG; 20MG; EQ 4MG BASE and 125MG; 50MG; EQ 10MG BASE
  • Therapeutic Category :

    Respiratory Agents
  • Revenue ($M) :

    838

Year-wise Projected Sales ($M) :

  • 2026 :

    1976
  • 2027 :

    2856
  • 2028 :

    3811
  • 2029 :

    4714
  • 2030 :

    5564
  • 2031 :

    6371
  • 2032 :

    7146
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?